Organic Pressurized Fluid Patents (Class 424/45)
-
Publication number: 20130189194Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.Type: ApplicationFiled: March 12, 2013Publication date: July 25, 2013Applicant: Boehringer Ingelheim Inrernational GmbHInventors: Thierry BOUYSSOU, Michael P. Pieper, Andreas Schnapp
-
Publication number: 20130189196Abstract: A foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alcohol free and is used in treating, alleviating or preventing a disorder.Type: ApplicationFiled: March 12, 2013Publication date: July 25, 2013Applicant: FOAMIX LTD.Inventor: Foamix Ltd.
-
Patent number: 8491872Abstract: Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. ?-O4 and ?-5 trimers and tetramers) are used as anticoagulants.Type: GrantFiled: August 4, 2009Date of Patent: July 23, 2013Assignee: Virginia Commonwealth UniversityInventors: Umesh R. Desai, Brian L. Henry, Aiye Liang, Jay Thakkar, John B. Mangrum, Ivo Torres Filho, Bruce D. Spiess, Masahiro Sakagami, Bhawana Saluja
-
Publication number: 20130183251Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.Type: ApplicationFiled: March 4, 2013Publication date: July 18, 2013Applicant: FOAMIX LTD.Inventor: Foamix Ltd.
-
Patent number: 8486374Abstract: A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.Type: GrantFiled: January 14, 2008Date of Patent: July 16, 2013Assignee: Foamix Ltd.Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Alex Besonov, David Schuz, Tal Berman, Jorge Danziger, Rita Keynan, Ella Zlatkis
-
Patent number: 8486375Abstract: The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.Type: GrantFiled: February 20, 2012Date of Patent: July 16, 2013Assignee: Foamix Ltd.Inventors: Dov Tamarkin, Doron Friedman, Meir Eini
-
Publication number: 20130177505Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: Kate Somerville Skin Care, LLCInventor: Kate Somerville Skin Care, LLC
-
Patent number: 8480952Abstract: A method of manufacturing liposome-containing preparations which contain liposomes exhibiting superior stability in vivo and high enclosure rate of a drug is disclosed, comprising mixing a supercritical or subcritical carbon dioxide, one or more liposome membrane constituents including a phospholipid exhibiting a phase transition temperature and a water-soluble chemical.Type: GrantFiled: July 22, 2005Date of Patent: July 9, 2013Assignee: Konica Minolta Medical & Graphic, Inc.Inventors: Chiaki Nagaike, Yasuyuki Motokui
-
Publication number: 20130167838Abstract: This invention relates to a solution formulation for nasal administration comprising azelastine, beclomethasone dipropionate, a co-solvent, an acid and an HFA propellant.Type: ApplicationFiled: December 7, 2012Publication date: July 4, 2013Applicant: TEVA BRANDED PHARMACEUTICAL PRODUCTS, INC.Inventor: Teva Branded Pharmaceutical Products, Inc.
-
Patent number: 8475769Abstract: A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active ingredient and a solvent blend. The solvent blend includes at least one low volatility solvent and at least one high volatility solvent wherein each has a defined vapor pressure and Hansen solubility parameter. The composition upon dispersion as a spray has an aerosol particle size of less than 30 microns.Type: GrantFiled: June 25, 2010Date of Patent: July 2, 2013Assignee: S.C. Johnson & Son, Inc.Inventors: Peter N. Nguyen, John R. Wietfeldt, Yemi Susan Bullen, Francis J. Randall, Randy C. Yuhas
-
Patent number: 8475770Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.Type: GrantFiled: September 2, 2011Date of Patent: July 2, 2013Assignee: Stiefel Research Australia Pty LtdInventors: Albert Zorko Abram, Lilian Fuchshuber
-
Publication number: 20130160761Abstract: A pharmaceutical aerosol composition comprising at least one hydrofluoroalkane propellant; at least one active agent complexed with an adjuvant; and, optionally, at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: November 27, 2012Publication date: June 27, 2013Applicant: CIPLA LIMITEDInventors: CIPLA LIMITED, Mustafa Khwaja Hamieel
-
Patent number: 8470301Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.Type: GrantFiled: November 11, 2011Date of Patent: June 25, 2013Assignee: Nektar TherapeuticsInventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
-
Patent number: 8470887Abstract: Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to support aerosol delivery, and the urea composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery device, a propellant.Type: GrantFiled: December 15, 2011Date of Patent: June 25, 2013Assignee: Quinnova Pharamaceuticals, Inc.Inventor: Mats Silvander
-
Publication number: 20130156823Abstract: Methods and compositions for producing formulations for orally inhaled benzodiazepines that do not require the presence of a surface modifier are described. The formulations are useful in the treatment of epileptic seizures.Type: ApplicationFiled: December 20, 2012Publication date: June 20, 2013Applicant: MAP Pharmacauticals, Inc.Inventor: MAP Pharmaceuticals, Inc.
-
Patent number: 8465728Abstract: An air treating composition for eliminating airborne malodors and/or sanitizing air in combination with a spray valve and actuator and spray performance parameters providing maximum dispersion of the composition is disclosed. The particles of the composition are small so that the active component is dispersed into air as a fine dispersion to provide more contact with malodors and to provide quick absorption of malodors and/or bacteria. The particle size of the composition is controlled through the valve and actuator dimensions, as well as the formulation requirements of the composition. The air treating composition includes water, a low molecular weight polyol, and a propellant. The composition may also include one or more adjuvants such as an emulsifier, a co-solvent, a fragrance, a corrosion inhibitor, a pH adjusting agent and the like.Type: GrantFiled: March 1, 2007Date of Patent: June 18, 2013Assignee: S.C. Johnson & Son, Inc.Inventors: Maciej K. Tasz, Leon C. Samuelson, Michael J. Roshier, Richard S. Valpey, III, Paul A. Clark, Jessica A. Heiser, Kendra L. Haag
-
Publication number: 20130150244Abstract: Pressurizing or propellant compositions and products made using the compositions are provided herein. The propellant compositions include ethane as a propellant. The ethane may be the only propellant in the composition or may be mixed with other propellants. The ethane may be the only hydrocarbon or the only saturated hydrocarbon propellant used in the compositions. Sprayable products including the propellants described herein are also provided. Finally methods of removing a contaminate from an article using the sprayable products described herein are also provided.Type: ApplicationFiled: December 12, 2012Publication date: June 13, 2013Applicant: DIVERSIFIED CPC INTERNATIONAL, INC.Inventor: Diversified CPC International., Inc.
-
Patent number: 8461211Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.Type: GrantFiled: December 30, 2010Date of Patent: June 11, 2013Assignee: AstraZeneca ABInventors: Carl-Axel Bauer, Jan Trofast
-
Publication number: 20130142868Abstract: Methods of delivering a pharmaceutical compounds directly to the olfactory epithelium of a mammal by providing a pharmaceutical aerosol suspension comprising an aerosol and the pharmaceutical compound; aerosolizing the suspension to generate a stream of droplets, the stream having a rotational component, and, delivering the droplets directly to the olfactory epithelium, wherein at least 15% of the droplets are delivered directly to the olfactory deposition. The pharmaceutical compound may be encapsulated within a liposome nanoparticle.Type: ApplicationFiled: August 19, 2011Publication date: June 6, 2013Applicant: UNIVERSITY OF WASHINGTONInventors: John D. Hoekman, Rodney J.Y. Ho
-
Publication number: 20130142879Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.Type: ApplicationFiled: January 29, 2013Publication date: June 6, 2013Applicants: INNOVATA BIOMED LIMITED, VECTURA LIMITEDInventors: VECTURA LIMITED, INNOVATA BIOMED LIMITED
-
Patent number: 8454938Abstract: A method for treating a mammal suffering from a respiratory disease characterized by acute intermittent or chronic obstruction of the airways of the lungs, such as asthma, acute asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis comprising delivering to the lungs of the mammal a perfluorocarbon and a gas mixture comprising carbon dioxide (CO2), and pharmaceutical compositions of CO2 and perfluorocarbons are provided. The acute relief of airway obstruction provided by the said treatment provides an opportunity for concomitant or subsequent delivery of additional suitable active agent of conventional treatments.Type: GrantFiled: December 21, 2006Date of Patent: June 4, 2013Assignee: Solaeromed Inc.Inventors: Francis H. Y. Green, Tamer Y. El Mays, Samuel Schurch
-
Patent number: 8449914Abstract: A controlled release pharmaceutical composition for oral use comprising carvedilol. The composition releases carvedilol after oral administration to a mammal, including a human, in such a manner that a prolonged residence of carvedilol is obtained in the circulatory system compared with the known compositions of carvedilol. Furthermore, a composition according to the present invention makes available to the body a suitable plasma concentration of one or both of the enantiomeric species, namely R(+) and/or S(?) carvedilol for obtaining the desired therapeutic effect.Type: GrantFiled: March 13, 2008Date of Patent: May 28, 2013Assignee: Egalet Ltd.Inventors: Christine Andersen, Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann
-
Publication number: 20130123720Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative and a corticosteroid, and its use in the treatment of dermal diseases and conditions. The spray comprises especially a propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether or a mixture thereof and further a pharmaceutically acceptable lipid carrier solubilised or suspended in said propellant.Type: ApplicationFiled: June 10, 2011Publication date: May 16, 2013Applicant: LEO PHARMA A/SInventors: Marianne Lind, Gritt Rasmussen, Mette Rydahl Sonne, Jens Hansen, Karsten Petersson
-
Patent number: 8440171Abstract: An air treating composition for eliminating odors from air in combination with specific spray valve and actuator requirements and spray performance parameters providing maximum dispersion of the active component in the composition into the air is disclosed. The particles of the composition are small so that the active component is dispersed into air as a fine dispersion to provide more contact with odors and to provide quick absorption of odors. The particle size of the composition is controlled through the selection of valve and actuator dimensions. The air treating and odor eliminating composition of the invention includes water, a low molecular weight polyol, an emulsifier, and a propellant. The composition may also include additional adjuvants such as solvent(s), fragrance(s), corrosion inhibitor, pH adjustor and the like.Type: GrantFiled: June 28, 2006Date of Patent: May 14, 2013Assignee: S.C. Johnson & Son, Inc.Inventors: Richard S. Valpey, III, Paul A. Clark, Maciej K. Tasz, Peter N. Nguyen
-
Publication number: 20130115173Abstract: Described herein are chemically-stabile formulations comprising a reactive propellant. The formulations are delivered as an aerosol foam, and are suitable for topical application. The aerosol propellant may be a hydrofluoroolefin propellant. The emulsions or compositions may comprise reactive active agents, such as peroxides, retinoids, or quinones. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Applicant: Precision Dermatology, Inc.Inventor: Precision Dermatology, Inc.
-
Patent number: 8435497Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.Type: GrantFiled: June 9, 2004Date of Patent: May 7, 2013Assignee: Takeda GmbHInventors: Klaus Dietzel, Helgert Mueller
-
Patent number: 8435547Abstract: A skin care composition is useful for augmenting cellular metabolism in skin cells and thereby enhancing the regulation of intracellular signaling. The composition comprises a primer for skin cell mitochondrial function, such as a Krebs cycle intermediate, a precursor of a Krebs cycle intermediate, salts or esters thereof, or combinations thereof. The composition may also include antioxidants for free radical regulation and a pharmaceutically acceptable topical vehicle, such as an emollient base for skin health. A method for stimulating the mitochondrial activity of skin cells comprises administering to the skin of a person in need thereof a composition as described herein.Type: GrantFiled: August 30, 2006Date of Patent: May 7, 2013Inventors: John P. Blass, Loretta Pratt, Steven Cosentino
-
Publication number: 20130108557Abstract: The present invention provides aerosol foams comprising Aloe vera. In particular, the foams comprise (a) Aloe vera, (b) a surfactant and (c) a propellant. The foams may further comprise one or more of the group consisting of an ?-hydroxy acid, a ?-hydroxy acid, a humectant, a thickening agent, a dermatologically acceptable excipient, and mixtures thereof.Type: ApplicationFiled: September 28, 2010Publication date: May 2, 2013Inventors: Albert Zorko Abram, Iulian Goldstein
-
Publication number: 20130098357Abstract: Pharmaceutical formulations and methods of using thereof for the treatment and prevention of pulmonary arterial hypertension are provided. The formulations contain one or more agents to simultaneously reduce ADMA levels in a patient and reduce inflammatory processes in the pulmonary vasculature of a patient. The formulations contain a therapeutically effective amount of cerivastatin, a cerivastatin analog, or a pharmaceutically acceptable salt, prodrug, clathrate, or solvate thereof in a carrier suitable for pulmonary administration.Type: ApplicationFiled: October 20, 2011Publication date: April 25, 2013Inventor: Jaipal Singh
-
Publication number: 20130101525Abstract: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.Type: ApplicationFiled: September 20, 2012Publication date: April 25, 2013Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTDInventors: Richard BUCHTA, Robert James HOULDEN, Maria Graziella LARM, Leon LOUPENOK, Rose YE
-
Publication number: 20130101526Abstract: The present invention provides compositions which not only effectively kill a broad spectrum of microorganisms present on surfaces on contact but continue to kill microorganisms for a period of time thereafter.Type: ApplicationFiled: December 10, 2012Publication date: April 25, 2013Applicant: RECKITT BENCKISER LLC.Inventor: Reckitt Benckiser LLC.
-
Publication number: 20130095044Abstract: A new microbial strain of the species Streptococcus salivarius for use in the treatment of inflammatory processes with or without infectious etiology. A further object of the present invention compositions including the strain and uses thereof.Type: ApplicationFiled: October 4, 2012Publication date: April 18, 2013Applicant: D.M.G. ITALIA SrlInventor: D.M.G. ITALIA Srl
-
Patent number: 8420060Abstract: Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurized metered dose inhalers (pMDIs).Type: GrantFiled: October 4, 2010Date of Patent: April 16, 2013Assignee: Chiesi Farmaceutici S.p.A.Inventor: Gaetano Brambilla
-
Patent number: 8420058Abstract: Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.Type: GrantFiled: August 26, 2009Date of Patent: April 16, 2013Assignee: Chiesi Farmaceutici S.p.A.Inventors: David Lewis, Davis Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
-
Patent number: 8420059Abstract: A single phase aerosol composition comprising the following constituents: (a) 5 to 75 wt % of a hydrofluorocarbon(s) (HFC) of vapor pressure greater than or equal to 4 bar at 20° C. (60 psig at 70° F.); (b) 10 to 30 wt % of a hydrocarbon propellant; (c) 1 to 70 wt % of a hydrocarbon solvent(s) with a vapor pressure of less than 0.1 mm Hg at 20° C.; (d) 0.01 to 10 wt % of an active constituent(s) selected from the group which includes fragrances, air-sanitisers, air fresheners, deodorizers, odor eliminators, malodor counteractants, insecticides, insect repellants, medicinal substances, disinfectants, aroma therapy compositions; and, (e) 0 to 25 wt % of an adjuvant constituent(s) other than (a), (b), (c) or (d). Methods of making the said composition and aerosol dispensers containing the said composition are also disclosed.Type: GrantFiled: August 23, 2010Date of Patent: April 16, 2013Assignee: Reckitt Benckiser (UK) LimitedInventors: Paul William Robinson, Claire Louise Hewson-Hyde, Andrea Szeki, John McNamara
-
Publication number: 20130089617Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.Type: ApplicationFiled: October 11, 2012Publication date: April 11, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130084251Abstract: The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water. The compounds are present in the water at a concentration ranging from 0.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Inventors: Robert Scott Osbakken, Russell N. Reitz, John C. Tarrant
-
Patent number: 8409549Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 ?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.Type: GrantFiled: April 13, 2011Date of Patent: April 2, 2013Assignee: Gilead Sciences, Inc.Inventors: William Baker, David MacLeod
-
Publication number: 20130078191Abstract: There is provided an aerosol composition which is high in fire safety and assures easy emulsification of an aqueous concentrate and a liquefied gas. The aerosol composition comprises 10 to 60 wt % of an aqueous concentrate and 40 to 90 wt % of a liquefied gas, and is obtained by emulsifying the aqueous concentrate and the liquefied gas, wherein the liquefied gas comprises a heavy liquefied gas (a) having a liquid density at 20° C. of from 1.15 to 1.30 (g/ml).Type: ApplicationFiled: June 13, 2011Publication date: March 28, 2013Applicant: DAIZO CORPORATIONInventors: Keiichiro Teramoto, Fuminori Okano, Atsushi Wagamitsu
-
Patent number: 8404217Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.Type: GrantFiled: July 22, 2005Date of Patent: March 26, 2013Assignee: Novartis AGInventors: Thomas E. Tarara, Jeffry G. Weers, Michael A. Eldon, Rangachari Narashimhan, Andrew Clark
-
Publication number: 20130071337Abstract: A composition comprising an interomone is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the interomone is a naturally occurring pheromone.Type: ApplicationFiled: September 20, 2012Publication date: March 21, 2013Applicant: Sergeant's Pet Care Products, Inc.Inventor: Sergeant's Pet Care Products, Inc.
-
Patent number: 8398957Abstract: An aerosol composition comprising: 0.01 wt % to 1.00 wt % sodium borate; 0.01 wt % to 1.50 wt % polyglycerol ester surfactant; <30 wt % propellant; and 67.5 wt % to 85.0 wt % water. Methods of manufacture of an aerosol air freshener are also described wherein the aerosol composition further comprises a fragrance.Type: GrantFiled: October 8, 2008Date of Patent: March 19, 2013Assignee: Reckitt Benckiser (UK) LimitedInventors: Chris Bates, Erin Corstanje, Chris Jones, Maud Portier, Hannah Tipple
-
Publication number: 20130039863Abstract: Methods of controlling the feeding and/or breeding behavior of a target insect are disclosed in which a host plant is provided a substantial distance from a plant of interest, chemical attractant that induces the target insect to lay eggs on the host plant is applied to the host plant, application of the chemical attractant to the host plant is repeated as required to induce residual target-insect populations to lay eggs on the host plant, and wherein the behavior is controlled when a substantial number of off-spring belonging to subsequent generations themselves mature and display a preference for laying eggs on the same type of host plant on which they were reared without further application of the chemical attractant is provided. Also disclosed are methods of deterring target insect feeding and breeding on plants of interest by applying toxic plant extract to the plants of interest.Type: ApplicationFiled: January 28, 2011Publication date: February 14, 2013Applicant: University of the West Indies a Regional Institution established by Royal CharterInventors: Trevor Herbert Yee, Charah Tabetha Watson, Eric Garraway
-
Patent number: 8367734Abstract: A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.Type: GrantFiled: May 7, 2010Date of Patent: February 5, 2013Assignee: Amphastar Pharmaceuticals Inc.Inventors: Jianxin Gao, James Luo, Rong Zhou, Mary Ziping Luo, Jack Yongfeng Zhang
-
Publication number: 20130028845Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.Type: ApplicationFiled: October 2, 2012Publication date: January 31, 2013Applicant: Sunovion Pharmaceuticals Inc.Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
-
Patent number: 8361444Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.Type: GrantFiled: December 14, 2010Date of Patent: January 29, 2013Assignee: Gilead Sciences, Inc.Inventors: William Baker, David MacLeod
-
Patent number: 8357352Abstract: Disclosed are propellant gas formulations containing at least one suspended active substance which contains chemically bound water, water and the propellant TG 227 or TG 134 a.Type: GrantFiled: June 29, 2005Date of Patent: January 22, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Christel Schmelzer, Arne Froemder
-
Patent number: 8354099Abstract: Composition of a Dead Sea extract and at least one plant extract of a Himalayan origin are provided for topical applications.Type: GrantFiled: October 6, 2009Date of Patent: January 15, 2013Assignee: Ahava-Dead Sea Laboratories Ltd.Inventors: Zeev Maor, Tamar Zioni
-
Publication number: 20130011342Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.Type: ApplicationFiled: October 1, 2010Publication date: January 10, 2013Applicant: FOAMIX LTD.Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan, Nukzi Papiashvile
-
Publication number: 20130011452Abstract: The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis; and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.Type: ApplicationFiled: July 20, 2012Publication date: January 10, 2013Inventor: Leon LOUPENOK